Judges, Not Juries, Should Decide ‘Clear Evidence’ in FDA Labeling Preemption Cases, SCOTUS Rules

Drug Industry Daily
Federal judges—and not juries—should say what constitutes “clear evidence” that the FDA would likely have rejected changes to a drug’s label, the Supreme Court ruled Monday in a decision that could have far-reaching impact on preemption cases.

To View This Article:


Subscribe To Drug Industry Daily